ZENTALIS PHARMACEUTICALS, INC.

Company

Zentalis Pharmaceuticals, Inc.

Filed

June 3, 2022

Accession Number

0000902664-22-003160

A Schedule 13D is filed when an investor acquires more than 5% of a company's shares with an intent to influence control. Learn more about SC 13D filings →